The pharmaceutical industry has been leading the way in its use of flow chemistry technology for research and development and manufacturing of new drugs, and Gedeon Richter is no exception. Using a Syrris Asia Flow Chemistry system, researchers have been able to create new heterocyclic scaffolds – chemistry that was impossible to them before adopting flow chemistry techniques.
Research Scientist, Dr. György Túrós, explains how the pharmaceutical giant is using Asia to access new chemistries
The Discovery Chemistry Department at Gedeon Richter in Budapest, Hungary, invested in an Asia flow chemistry system to aid researchers involved in the design and synthesis of original central nervous system (CNS) drugs. Research scientist Dr. György Túrós explained:
“In discovery chemistry research, we need to perform a lot of very interesting and complex chemical syntheses and, until now, have relied on classical batch chemistry methods.
We purchased an Asia flow chemistry reactor in June 2012, and are reaping the benefits of using flow chemistry techniques. The system has extended the range of chemistries available to us, allowing us to work at much higher pressures and temperatures – sometimes above a solvent’s boiling point – to create completely new heterocyclic scaffolds.
We can combine the Asia modules in a variety of different ways to meet changing needs, and will also be able to add additional modules at a later date if required. This was an important consideration, and one of the main reasons for choosing Asia.
Syrris has been very supportive, giving us some valuable ideas and flow chemistry tips during our training, and we can now do chemistry which was absolutely impossible before. In my opinion, Syrris is as innovative in the synthetic chemistry arena as Google or Apple in the informatics field.”